Table 1. Baseline characteristics of the SPRINT trial participants included for model derivation (N = 9,069) and ACCORD-BP trial participants included for model validation (N = 4,498).
| Characteristic | Included SPRINT sample | Included ACCORD-BP sample | ||||
|---|---|---|---|---|---|---|
| Intensive treatment arm (N = 4,555) | Standard treatment arm (N = 4,514) | P value | Intensive treatment arm (N = 2,243) | Standard treatment arm (N = 2,255) | P value | |
| Demographics | ||||||
| Age, mean (SD), y | 67.9 (9.4) | 67.8 (9.4) | 0.66 | 63.2 (6.6) | 63.1 (6.7) | 0.87 |
| Senior in age, ≥75 y | 1,287 (28.3) | 1,261 (27.9) | 0.75 | 117 (5.2) | 143 (6.3) | 0.12 |
| Women | 1,630 (35.8) | 1,579 (35.0) | 0.44 | 1,102 (49.1) | 1,099 (48.7) | 0.81 |
| Race/ethnicity | ||||||
| Black race | 1,412 (31.0) | 1,447 (32.1) | 0.29 | 517 (23.0) | 545 (24.2) | 0.40 |
| Hispanic ethnic group | 494 (10.8) | 470 (10.4) | 0.53 | 162 (7.2) | 157 (7.0) | 0.78 |
| Smoking | ||||||
| Ever smoker | 2,557 (56.1) | 2,522 (55.9) | 0.82 | 1,114 (49.7) | 1,112 (49.3) | 0.84 |
| Current smoker | 627 (13.8) | 588 (13.0) | 0.32 | 23 (1.0) | 26 (1.2) | 0.79 |
| Former smoker | 1,930 (42.4) | 1,934 (42.8) | 0.66 | 1,091 (48.6) | 1,086 (48.2) | 0.77 |
| Clinical measures | ||||||
| Seated systolic BP, mean (SD), mm Hg | 139.6 (15.8) | 139.7 (15.4) | 0.94 | 139.4 (16.1) | 139.7 (15.3) | 0.55 |
| Seated diastolic BP, mean (SD), mm Hg | 78.2 (11.9) | 78.1 (12.0) | 0.66 | 75.8 (10.3) | 76.0 (10.3) | 0.63 |
| Serum creatinine, mean (SD), μmol/l [mg/dl] | 97.3 (26.5) [1.1 (0.3)] |
97.3 (26.5) [1.1 (0.3)] |
0.64 | 79.6 (17.7) [0.9 (0.2)] |
79.6 (17.7) [0.9 (0.2)] |
0.55 |
| Urine microalbumin/creatinine, mean (SD), mg/mmol [mg/g] | 4.9 (20.1) [43.7 (178.3)] |
4.7 (17.4) [41.3 (154.0)] |
0.51 | 9.2 (30.4) [81.4 (269.4)] |
10.7 (39.0) [94.9 (344.9)] |
0.15 |
| Total cholesterol, mean (SD), mmol/l [mg/dl] | 4.9 (1.1) [190.1 (41.4)] |
4.9 (1.1) [190.1 (41.0)] |
0.97 | 5.0 (1.1) [194.5 (44.4)] |
4.9 (1.1) [191.1 (43.0)] |
0.01 |
| Direct high-density lipoprotein cholesterol, mean (SD), mmol/l [mg/dl] | 1.4 (0.4) [52.9 (14.4)] |
1.4 (0.4) [52.7 (14.5)] |
0.63 | 1.2 (0.3) [46.7 (13.2)] |
1.2 (0.4) [46.7 (13.8)] |
0.92 |
| Triglycerides, mean (SD), mmol/l [mg/dl] | 1.4 (1.0) [125.1 (86.4)] |
1.4 (1.1) [127.1 (94.1)] |
0.29 | 2.1 (1.9) [188.6 (166.6)] |
2.1 (1.8) [185.2 (162.5)] |
0.50 |
| Body mass index, mean (SD), kg/m2 | 29.9 (5.8) | 29.8 (5.7) | 0.39 | 32.3 (5.6) | 32.2 (5.3) | 0.33 |
| Medication utilization | ||||||
| BP treatment agents prior to randomization, mean (range) | 1.8 (0–6) | 1.8 (0–5) | 0.49 | 1.7 (0–6) | 1.7 (0–5) | 0.33 |
| Daily aspirin use | 2,356 (51.7) | 2,345 (50.5) | 0.24 | 1,203 (53.6) | 1,155 (51.2) | 0.11 |
| Statin use | 1,949 (42.8) | 2,019 (44.7) | 0.07 | 1433 (63.9) | 1476 (65.5) | 0.29 |
Data are given as number (percent) unless otherwise indicated.
BP, blood pressure.